In a groundbreaking study, researchers led by Pimentel, Teixeira, and Soares have unveiled remarkable insights into kaurenoic acid, a compound derived from the by-products of synthetic biology. Their work not…
PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies.…
AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) in collaboration with the Brush and Key Foundation, today announced the publication of a peer-reviewed research…
, /PRNewswire/ — LifeNet Health, a global leader in regenerative medicine, has acquired Tissue Testing Technologies LLC (T3), a biotechnology company specializing in biopreservation. T3 ‘s advanced proprietary technologies and…
New Team Members Bring Experience and Strategic Vision , /PRNewswire/ — Pivot Bio, one of the world’s leading innovative agtech companies, today announced six seasoned professionals have joined its senior…
SPR announces 50,000 SPRINT PNS implants Dr. Christopher Gilmore and team performed the milestone 50,000th SPRINT PNS implant. CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) — SPR announced that it has…
MILAN, Dec. 15, 2025 (GLOBE NEWSWIRE) — BetaGlue® Therapeutics (“BetaGlue” or the “Company”), a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid…
Combining breakthrough blood-based test with same-week access to board-certified hepatologists in all 50 states , /PRNewswire/ — Helio Genomics (“Helio” or “the Company”), an AI-driven techbio company specializing in diagnostics…
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs , /PRNewswire/ — Lunit (KRX:328130), a…
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest that nuclear GSK-3β expression may help identify patients most likely…